Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

‘Casodex’ (bicalutamide) 150mg a cost effective treatment for the management of locally advanced prostate cancer[1]

18.01.2005


New health economic data published in the European Journal of Hospital Pharmacy outline the cost benefits of the non-steroidal anti-androgen bicalutamide 150mg for the treatment of locally advanced prostate cancer. By delaying disease progression in patients with locally advanced prostate cancer, bicalutamide 150mg reduces the additional healthcare costs associated with treating advanced disease.



The paper by Dr Heather Payne, Middlesex Hospital UCL, London states that bicalutamide 150mg impacts less on healthcare budgets compared to other types of cancer treatments.1* An analysis of the cost-effectiveness of bicalutamide 150mg based on the first analysis of the Early Prostate Cancer (EPC) Trial, shows that its estimated cost-effectiveness per quality-adjusted life year (£10,067) falls well below the commonly used threshold for cost-effectiveness (£29,212) and compares well with the cost-utilities of other approaches used in oncology.2,3

The cost of bicalutamide 150mg (administered for three years) plus radical prostatectomy or radiotherapy for locally advanced prostate cancer is also significantly lower compared to the cost of other oncology treatments.2,3


Progression of locally advanced prostate cancer can result in costly complications such as bone metastases and serious skeletal complications.4

In addition, Dr Payne highlights in her paper, that bicalutamide 150mg gives a significant improvement in progression-free survival in patients with locally advanced disease, reducing the risk of objective disease progression by 42% in radiotherapy patients, 47% in watchful waiting patients, and 29% in radical prostatectomy patients.5

As well as being as effective as castration in prolonging survival in non-metastatic prostate cancer6, bicalutamide 150mg has significant quality-of-life benefits, with improvements over castration-based therapies in terms of maintaining bone mineral density, physical capacity and sexual activity.6,7 A recent study of the risk of osteoporosis in men with non-metastatic prostate cancer revealed that those who were treated with bicalutamide 150mg maintained bone mineral density (BMD), whilst those who received castration were associated with a progressive loss of BMD, which can result in costly complications such as increased risk of fractures.7

Dr Payne concludes: “Bicalutamide 150mg is a cost-effective therapy for patients with locally advanced prostate cancer, delaying disease progression, and offers a valuable alternative to castration in this setting”.

Bicalutamide 150mg is indicated in the UK in patients with locally advanced prostate cancer (T3-T4, any N, MO; T1-T2, N+, MO), as immediate therapy either alone or as adjuvant to treatment by radical prostatectomy or radiotherapy. Bicalutamide 150mg is also indicated for the management of patients with locally advanced, non-metastatic prostate cancer for whom surgical castration or other medical intervention is not considered appropriate or acceptable.8

*Data is based on UK NHS costs and may vary in other countries

References:

1. Payne, H. The value of delaying disease progression with bicalutamide (‘Casodex’) 150mg in locally advanced prostate cancer. European Journal of Hospital Pharmacy. 2004.

2. Moeremans K, Caekelbergh K, Annemans L. Cost-effectiveness analysis of bicalutamide (CasodexTM) for adjuvant treatment of early prostate cancer. Value Health 2004; 7: 472-81.

3. Earle CC, Chapman RH, Baker CS, Bell CM, Stone PW, Sandberg EA, Neumann PJ.

Systematic overview of cost-utility assessments in oncology. J Clin Oncol 2000; 18:3302-17.

4. Groot MT, Boeken Kruger CG, Pelger RC, Uyl-de Groot CA. Costs of prostate cancer,

metastatic to the bone, in the Netherlands. Eur Urol 2003; 43: 226-32.

5. Wirth M et al. Bicalutamide (Casodex) 150mg as adjuvant to radical prostatectomy significantly increases progression-free survival in patients with early non-metastatic prostate cancer: analysis at a median follow-up of 5.4 years. J Urol. 2004; 172: 1865–1870.

6. Iversen P, Tyrell CJ, Kaisary AV et al Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. J.Urol 2000; 164: 1579-1582.

7. Sieber PR, Keiller DL, Kahnoski RJ et al Bicalutamide 150 mg maintains bone mineral density during monotherapy for localized or locally advanced prostate cancer. Urology 2004; 171: 2272-6.

8. AstraZeneca; Casodex (bicalutamide)150mg Summary of Product Characteristics.

Bea Shake | alfa
Further information:
http://www.hillandknowlton.com

More articles from Health and Medicine:

nachricht On track to heal leukaemia
18.01.2017 | Universitätsspital Bern

nachricht Penn vet research identifies new target for taming Ebola
12.01.2017 | University of Pennsylvania

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: How gut bacteria can make us ill

HZI researchers decipher infection mechanisms of Yersinia and immune responses of the host

Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...

Im Focus: Interfacial Superconductivity: Magnetic and superconducting order revealed simultaneously

Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.

While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...

Im Focus: Studying fundamental particles in materials

Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales

Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...

Im Focus: Designing Architecture with Solar Building Envelopes

Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.

As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...

Im Focus: How to inflate a hardened concrete shell with a weight of 80 t

At TU Wien, an alternative for resource intensive formwork for the construction of concrete domes was developed. It is now used in a test dome for the Austrian Federal Railways Infrastructure (ÖBB Infrastruktur).

Concrete shells are efficient structures, but not very resource efficient. The formwork for the construction of concrete domes alone requires a high amount of...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

12V, 48V, high-voltage – trends in E/E automotive architecture

10.01.2017 | Event News

2nd Conference on Non-Textual Information on 10 and 11 May 2017 in Hannover

09.01.2017 | Event News

Nothing will happen without batteries making it happen!

05.01.2017 | Event News

 
Latest News

A big nano boost for solar cells

18.01.2017 | Power and Electrical Engineering

Glass's off-kilter harmonies

18.01.2017 | Materials Sciences

Toward a 'smart' patch that automatically delivers insulin when needed

18.01.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>